Sequenta
Stage
Acquired | AcquiredTotal Raised
$43.46MAbout Sequenta
Sequenta is a biotechnology company dedicated to improving patient care in diseases mediated by immune cells through the discovery and development of novel clinical diagnostics. Sequenta markets a laboratory developed test for use in the diagnosis and monitoring of minimal residual disease in blood cancers.
Missing: Sequenta's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Sequenta's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Sequenta
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Sequenta is included in 4 Expert Collections, including Medical Devices.
Medical Devices
8,633 items
Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.
Health Monitoring & Diagnostics
2,623 items
Companies developing or offering products that aid in the assessment, screening, diagnosis, or monitoring of a person's state of health/wellness. Excludes companies focused solely on fitness/sports performance
Cancer
3,605 items
Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.
Health IT
7,901 items
Sequenta Patents
Sequenta has filed 34 patents.
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
3/4/2013 | 9/18/2018 | Molecular biology, Immune system, Clusters of differentiation, Transcription factors, Immunology | Grant |
Application Date | 3/4/2013 |
|---|---|
Grant Date | 9/18/2018 |
Title | |
Related Topics | Molecular biology, Immune system, Clusters of differentiation, Transcription factors, Immunology |
Status | Grant |
Latest Sequenta News
May 6, 2015
VentureWire , May 06, 2015, (c) 2015 Dow Jones & Company, Inc. Adaptive Biotechnologies Corp ., which recently acquired venture-backed diagnostics company Sequenta Inc ., has raised $195 million in a Series F financing that brings its total equity funding to $400 million. Adaptive uses next-generation sequencing to profile receptors on the surface of T cells and B cells of the immune system. These receptors scan the "bar codes" of pathogen invaders. When these receptors find a match, they launch an immune cascade that leads to the destruction of these pathogens and to the immune system's memory of them.... Document DJFVW00120150506eb56qb6id To continue reading this story login at the top right or try the product Document DJFVW00120150506eb56qb6id Exclusive news and deep analysis of what’s really happening with venture capital-backed companies, their investors,and their management teams.
Sequenta Frequently Asked Questions (FAQ)
Where is Sequenta's headquarters?
Sequenta's headquarters is located at 400 E Jamie Court, South San Francisco.
What is Sequenta's latest funding round?
Sequenta's latest funding round is Acquired.
How much did Sequenta raise?
Sequenta raised a total of $43.46M.
Who are the investors of Sequenta?
Investors of Sequenta include Adaptive Biotechnologies, Celgene, Mohr Davidow Ventures, Medicxi Ventures, Foresite Capital and 3 more.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.